Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23847255 | 0.86 | ALDH1A1 (0.34) | ALDH1A1HRH2HRH1HRH3CA2 | |
| SCHEMBL11571795 | 0.77 | ALDH1A1 (0.45) | ALDH1A1HRH2HRH1L3MBTL1KDM4E | |
| SCHEMBL4383363 | 0.77 | USP2 (0.42) | ALDH1A1HRH3MEN1KMT2AL3MBTL1 | |
| SCHEMBL21733078 | 0.76 | CHRM3 (0.33) | ALDH1A1HRH2HRH1CHRM3CA1 | |
| SCHEMBL23490206 | 0.74 | SMPD1 (0.31) | — | |
| SCHEMBL9070252 | 0.73 | OPRM1 (0.44) | CA1TP53MEN1KMT2AKDM2B | |
| SCHEMBL20160499 | 0.73 | USP2 (0.44) | ALDH1A1HRH3MEN1KMT2AL3MBTL1 | |
| SCHEMBL21348984 | 0.73 | HTR1A (0.43) | ALDH1A1KDM4E | |
| SCHEMBL881484 | 0.73 | GNAI3 (0.54) | MEN1KMT2AL3MBTL1GNAI3GNAI1 | |
| SCHEMBL21374418 | 0.72 | SMPD1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384105-B2 | Processes for preparing oligomers | SAREPTA THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210198296-A1 | PROCESSES FOR PREPARING OLIGOMERS | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20200362339-A1 | PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198296-A1 | PROCESSES FOR PREPARING OLIGOMERS | PCBP1, RNGTT, PHAX | ALDH1A1 4252/4885HRH2 4882/4885HRH1 4859/4885 |
| US-11384105-B2 | Processes for preparing oligomers | NOP2, RNGTT, PCBP1 | ALDH1A1 4482/4885HRH2 4885/4885HRH1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.